Generic version of OAB drug now available

June 10, 2013

A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.

A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.

Perrigo Co. said it had previously prevailed in litigation related to the drug’s launch at both the district and appellate levels. The product has begun shipping immediately, according to the company.

Trospium, also marketed under the brand name Sanctura XR, is a once-daily medication for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Related Content

PTNS therapy for OAB found durable at 3 years

 

Newer overactive bladder agent viable alternative to antimuscarinics